机构：[1]Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.[2]Department of Pathology, The First Affiliated Hospital of Guangxi Traditional Chinese Medicine, Nanning, 530023, Guangxi, China.[3]Department of Population Sciences, City of Hope National Medical Center, Duarte, 91010, CA, USA.[4]Department of Pathology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.[5]Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.[6]Department of Pathology, Huayin Medical Laboratory, Guangzhou, 510670, Guangdong, China.
Tetraspanins have been implicated in multiple biological functions including protein networking and cell signaling. NET-6 (TSPAN 13) has been demonstrated to be a tumor suppressor gene in breast cancer, while CD151 is more likely to act as an oncogene. However, the biological function of both proteins is still inconclusive. Immunohistochemistry was used to analyze the expression of NET-6 and CD151 proteins in breast tumors and benign epithelial cells. The cellular expression of both markers was correlated with HER2, ER, and PR status as well as tumor grade, Ki-67 scores, invasion, and metastasis. Expression of NET-6 and CD151 was variable both in tumors and in benign epithelial cells. Expression of NET-6 and CD151 was stronger in tumors than in benign epithelial cells. The expression of NET-6 was also stronger in HER2-negative, low-grade, lymphovascular invasion-negative, and non-metastatic breast tumors. There was no correlation between NET-6 expression and ER, or PR, or triple-negative status. There was no correlation between CD151 expression and HER2, ER, PR, or triple-negative status, tumor grade, or Ki-67 scores, invasion, and metastasis. The expression of tetraspanins NET-6 and CD151 may indicate an alteration of their biological function during neoplastic transformation. NET-6 expression in tumors might be a potential marker indicating the outcome of breast cancer.
基金：
Guangxi
Bureau of Science and Technology, No. 1598013-3 (PI: Huayi Huang)
and No. 2017GXNSFAA198043 (PI: Huayi Huang) and a grant from
The Health and Family Planning Commission of Guangxi Zhuang
Autonomous Region, No. Z2015353 (PI: Huayi Huang).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|3 区医学
小类|3 区医学：研究与实验
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验
第一作者：
第一作者机构：[1]Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, Guangxi, China.[5]Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
推荐引用方式(GB/T 7714)：
Jiang Liejun,Zhang Xiliu,Geradts Joseph,et al.Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker.[J].Clinical and experimental medicine.2019,19(3):377-384.doi:10.1007/s10238-019-00554-x.
APA：
Jiang Liejun,Zhang Xiliu,Geradts Joseph,Wei Qiang,Hochwald Steven...&Huang Huayi.(2019).Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker..Clinical and experimental medicine,19,(3)
MLA：
Jiang Liejun,et al."Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker.".Clinical and experimental medicine 19..3(2019):377-384
